Home > Resources > Company Profiles > Wyeth

Wyeth (WYE)

Email Confirmation

Bernard J. Poussot , President/Director/CEO/Chairman of the Board

www.wyeth.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company is engaged in the discovery, development, manufacture, distribution and sale of a diversified line of products in three primary businesses: Pharmaceuticals, Consumer Healthcare and Animal Health.

Press Releases

Guidance Software Shares Expertise at eDiscovery Event for Pharmaceutical, Biotech and Medical Device Industries Sep-04-2008, 05:27PM EDT
Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules Sep-04-2008, 03:51PM EDT
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers Sep-04-2008, 03:22PM EDT
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications Sep-03-2008, 03:14PM EDT
Research and Markets: An Analysis of Wyeth, One of the Top 10 World's Leading Pharmaceutical Companies: Analysing Marketing Tactics, Technology and Strategy Aug-28-2008, 09:00AM EDT

News From Around the Web

News

Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers (Medical News Today)

Sep 06 2008
Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules (Genetic Engineering News)

Sep 04 2008
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications (Examiner)

Sep 03 2008
Radio's Top 10 Spots (Radio & Records)

Sep 02 2008
Excessive Sleepiness (Modern Medicine)

Aug 15 2008
A multitasking multivitamin? (Consumer Reports)

Jul 17 2008
Quish announces her resignation from US Can (CIO Magazine)

Jul 03 2008

Employees

Number of Employees: 50,527

Revenue per Employee: $436,605

Top Executives

Mary Katherine Wold, Divisional Senior VP

Geno J. Germano, President, Divisional

Charles A. Portwood, Divisional President

E. Thomas Corcoran, Divisional President

John C. Kelly, CPA, Vice President/Controller

Thomas Hofstaetter, Ph.D., Divisional Senior VP

Richard R. DeLuca, Jr., President, Divisional

Timothy P. Cost, Senior VP, Divisional

Dr. Robert R. Ruffolo, Jr., Ph.D., Divisional President/Senior VP

Lawrence V. Stein, Senior VP/General Counsel

Douglas A. Rogers, President, Subsidiary

Gregory Norden, CFO/Senior VP

Joseph M. Mahady, Senior VP/President, Divisional

Rene R. Lewin, Divisional Senior VP

Ulf Wiinberg, Divisional President/Senior VP

Marily H. Rhudy, Divisional Senior VP

Cavan M. Redmond, President, Divisional

Denise M. Peppard, Senior VP, Divisional

Board of Directors

Victor F. Ganzi, Director

John P. Mascotte, Director

Gary L. Rogers, Director

Ivan G. Seidenberg, Director

Dr.Robert S. Langer, Sc.D., Director

John R. Torell, III, Director

Walter V. Shipley, Director

Dr.Frances D. Fergusson, Ph.D., Director

Professer John D. Feerick, Director

Michael J. Critelli, Director Nominee

Robert M. Amen, Director

Raymond J. McGuire, Director

Dr.Mary Lake Polan, M.D., Ph.D., M.P.H., Director

Financials

Quarterly

Annual

Income Statement	08/2008	04/2008	02/2008	10/2007
Sales	1.44 Bil.	1.56 Bil.	1.69 Bil.	1.39 Bil.
Gross Operating Profit	4.51 Bil.	4.15 Bil.	4.07 Bil.	4.23 Bil.
Operating Income before D & A (EBITDA)	1.84 Bil.	1.59 Bil.	1.31 Bil.	1.76 Bil.
Total Income Before Interest Expenses (EBIT)	1.62 Bil.	1.76 Bil.	1.36 Bil.	1.79 Bil.
Total Net Income	1.12 Bil.	1.2 Bil.	1.02 Bil.	1.15 Bil.
Basic EPS, Total	0.84	0.9	0.76	0.85
Diluted EPS, Total	0.83	0.89	0.75	0.84

BALANCE STATEMENT	08/2008	04/2008	02/2008	10/2007
Cash and Equivalents	10.38 Bil.	NA	NA	9.84 Bil.
Total Assets	23.14 Bil.	NA	NA	22.82 Bil.
Total Liabilities	6.02 Bil.	NA	NA	8.44 Bil.
Total Capitalization	31.22 Bil.	NA	NA	28.36 Bil.

Cash Flow	08/2008	04/2008	02/2008	10/2007
Net Cash From Continuing Operations	1.87 Bil.	NA	NA	4.27 Bil.
Net Cash From Investing Activities	-602.67 Mil.	NA	NA	-2.18 Bil.
Net Cash From Financing Activities	-1.36 Bil.	NA	NA	933.87 Mil.
Net Change in Cash & Cash Equivalents	-71.25 Mil.	NA	NA	3.06 Bil.

Income Statement	2008	2007	2006	2005
Sales	6.31 Bil.	4.78 Bil.	4.64 Bil.	4.32 Bil.
Gross Operating Profit	16.09 Bil.	15.57 Bil.	14.11 Bil.	13.03 Bil.
Operating Income before D & A (EBITDA)	6.08 Bil.	5.95 Bil.	5.24 Bil.	4.77 Bil.
Total Income Before Interest Expenses (EBIT)	6.46 Bil.	5.93 Bil.	4.86 Bil.	-19.54 Mil.
Total Net Income	4.62 Bil.	4.2 Bil.	3.66 Bil.	1.23 Bil.
Basic EPS, Total	3.44	3.12	2.73	0.93
Diluted EPS, Total	3.38	3.08	2.7	0.91

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	6.78 Bil.	7.62 Bil.	4.74 Bil.
Total Assets	NA	17.51 Bil.	18.04 Bil.	14.44 Bil.
Total Liabilities	NA	7.22 Bil.	9.95 Bil.	8.54 Bil.
Total Capitalization	NA	23.75 Bil.	21.23 Bil.	17.64 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	3.25 Bil.	2.35 Bil.	2.88 Bil.
Net Cash From Investing Activities	NA	-2.65 Bil.	317.08 Mil.	-1.55 Bil.
Net Cash From Financing Activities	NA	-1.47 Bil.	229.53 Mil.	-2.68 Bil.
Net Change in Cash & Cash Equivalents	NA	-837.58 Mil.	2.87 Bil.	-1.33 Bil.

Wyeth (WYE)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request